New asthma inhaler shows promise in early safety trial
NCT ID NCT06795906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental inhaler called AZD8630 in 24 adults with asthma who already use medium-to-high dose steroid inhalers and long-acting bronchodilators. Participants took the drug once daily for 2 weeks to check its safety, how the body processes it, and its effect on airway inflammation. The goal was to see if it is safe enough for further testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Ahrensburg, 22926, Germany
-
Research Site
Berlin, 10119, Germany
-
Research Site
Mainz, 55128, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?